REGENERON PHARMACEUTICALS, INC. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0000872589

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltBuy & Hold how tags are computed

Q4 2024 · 6 positions · Total reported value $1.09B · Top-10 concentration 100.0% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 0.0% · 0 new · 0 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q4 2024 13F filing, REGENERON PHARMACEUTICALS, INC. disclosed 6 equity positions with a combined reported value of $1.09B. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / Buy & Hold.

The largest disclosed positions as of Q4 2024 were ALNY ($1.05B), NTLA ($43.18M), TSVT ($3.69M). By sector, the heaviest allocations are Health Care 99.6%, Other 0.4%.

Versus the prior quarter, REGENERON PHARMACEUTICALS, INC. opened 0 new positions, trimmed 0 and fully exited 0, a turnover rate of 0.0% of positions.

The largest new positions opened in Q4 2024 were ALNY ($1.05B), NTLA ($43.18M), TSVT ($3.69M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2024)

  • ALNY Alnylam Pharmaceuticals Inc · $1.05B
  • NTLA Intellia Therapeutics, Inc. · $43.18M
  • TSVT 2SEVENTY BIO INC · $3.69M
  • ACET Adicet Bio, Inc. · $931.39K
  • ADVM ADVERUM BIOTECHNOLOGIES INC · $844.85K
  • BLUE BLUEBIRD BIO INC · $175.14K

Fully Exited (vs previous quarter)

No tracked position was fully exited this quarter.

Insider Transactions (Form 4)

Latest REGENERON PHARMACEUTICALS, INC. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Regeneron Pharmaceuticals files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 3 positions worth $177.22M in total. HoldingsHub carries 7 quarters of its filings (Q4 2024–Q2 2026).

Portfolio Structure

  • 3 positions · $177.22M reported value (Q2 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: PBLS (PARABILIS MEDICINES INC) at 64.4%
  • Average position size: $59.07M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 1 new
  • 2 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 99.6%
Other 0.4%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 4.44M $1.05B 95.54%
95.54%
New
2 3.70M $43.18M 3.94%
3.94%
New
3 1.25M $3.69M 0.34%
0.34%
New
4 968.18K $931.39K 0.09%
0.09%
New
5 180.91K $844.85K 0.08%
0.08%
New
6 21.00K $175.14K 0.02%
0.02%
New

FAQ

What did REGENERON PHARMACEUTICALS, INC. buy in 2024-Q4?

In its 2024-Q4 13F filing, REGENERON PHARMACEUTICALS, INC. reported 6 equity positions worth $1.09B in aggregate; its largest disclosed positions were ALNY ($1.05B), NTLA ($43.18M), TSVT ($3.69M).

How large is REGENERON PHARMACEUTICALS, INC.'s portfolio?

REGENERON PHARMACEUTICALS, INC. reported $1.09B of long equity holdings across 6 positions as of 2024-Q4. Top-10 holdings account for 100.0% of reported value.

What is REGENERON PHARMACEUTICALS, INC.'s investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / Buy & Hold, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/regeneron-pharmaceuticals/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →